成都凡诺西生物医药科技

Pharmanovo is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, focused on developing next-generation therapies for metabolic diseases and oncology. The company utilizes a proprietary structure-based drug design (SBDD) platform to create highly selective small molecule and peptide drugs. Its primary focus is on the incretin pathway, with a pipeline featuring oral small molecule GLP-1 receptor agonists and multi-target agonists (GLP-1/GIP/GCG). Pharmanovo's lead candidate, FNX-001, is currently in clinical development for the treatment of type 2 diabetes and obesity. By targeting high-prevalence chronic conditions, the company aims to deliver innovative and patient-friendly therapeutic solutions to the global market.